Amarin (AMRN) Says FDA Panel Meeting Will Not Be Scheduled Related to NDA for AMR101

Amarin Corporation plc (Nasdaq: AMRN) announced today that it was informed by the U.S. FDA that no advisory committee meeting will be scheduled in connection with the FDA's review of the NDA seeking approval for the use AMR101 in the treatment of patients with very high triglycerides (≥500mg/dL), the company's lead product candidate. The FDA has previously assigned a Prescription Drug User Fee Act (PDUFA) date of July 26, 2012 for completion of its review of the AMR101 NDA.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• JPMorgan Reinstates Amarin Corporation (AMRN) at Underweight
• loanDepot receives NYSE non-compliance notice over stock price
• FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris